Lorlatinib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 849 publications
US population-level model of clinical impact of lorlatinib treatment on ALK+ metastatic non-small cell lung cancer outcomes.
Journal: Journal of comparative effectiveness research
Published: September 03, 2026
First-Line Lorlatinib for ALK-Rearranged Pulmonary Large-Cell Neuroendocrine Carcinoma with Brain Metastases and Suspected Leptomeningeal Involvement: A Case Report and Literature Review.
Journal: Internal medicine (Tokyo, Japan)
Published: August 19, 2026
Incidence, Management, and Clinical Outcomes of Cardiovascular Adverse Events in Patients Receiving ALK Inhibitors for Advanced Non-Small Cell Lung Cancer: A Real-World Single-Center Analysis.
Journal: Cancer investigation
Published: August 11, 2026
Concurrent Treatment With Lorlatinib and Dinutuximab Beta Induced Acute Gastric Dilation in a Pediatric Patient With Neuroblastoma.
Journal: Pediatric blood & cancer
Published: July 27, 2026
Expert consensus on iruplinalkib for the treatment of ALK-positive non-small cell lung cancer (2026 edition)
Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]
Published: July 25, 2026
Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK.
Journal: Lung cancer management
Published: July 21, 2026
A novel MYO5C-ALK fusion in lung adenocarcinoma: limited alectinib response and durable lorlatinib benefit.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 28, 2026
Acquired EML4-ALK fusion and BRAF V600G dual bypass activation following osimertinib resistance in lung adenocarcinoma and successful treatment with lorlatinib: a case report.
Journal: Frontiers in oncology
Published: June 25, 2026
Longitudinal Treatment Outcomes in Patients With Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer: Results From a Multinational Registry-Based Study in a Predominantly Western Population.
Journal: JCO global oncology
Published: June 24, 2026
Lorlatinib: the crown jewel of ALK inhibitors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 15, 2026
Physiologically based pharmacokinetic model of two ALK inhibitors to inform drug and dosing regimens for brain metastasis patients.
Journal: Frontiers in pharmacology
Published: June 06, 2026
Last Updated: 09/26/2026